Search

Displaying results 8861 - 8870 of 9686 in total
  1. Drug

    SGN-1

    go.drugbank.com/drugs/DB18135
    Investigational

    SGN-1 is a genetically modified strain of _Salmonella enterica_ comprising methioninase.

  2. Drug

    Xaluritamig

    go.drugbank.com/drugs/DB18137
    Investigational

    Xaluritamig is a novel humanized bispecific T cell recruiting antibody cross-reactive to human and nonhuman primate STEAP1 and CD3.

  3. Drug

    SBT101

    go.drugbank.com/drugs/DB18139
    Investigational

    SBT101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector containing the human adenosine triphosphate (ATP)-binding cassette (ABC) sub-family D member 1 (ABCD1

  4. Drug

    BBT-059

    go.drugbank.com/drugs/DB18142
    Experimental

    BBT-059 is a long-acting interleukin-11 analog.

  5. Drug

    NRP-2945

    go.drugbank.com/drugs/DB18150
    Experimental

    NRP-2945 is a 11-mer peptidomimetic.

  6. Drug

    Zilganersen

    go.drugbank.com/drugs/DB18161
    ApprovedInvestigational

    Zilganersen is a glial fibrillary acidic protein (GFAP)-directed antisense oligonucleotide used to treat Alexander disease.

  7. Drug

    BBP-711

    go.drugbank.com/drugs/DB18199
    Investigational

    BBP-711 is a glycolate oxidase inhibitor.

  8. Drug

    Andusomeran

    go.drugbank.com/drugs/DB18227
    ApprovedInvestigational

    Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g.

  9. Drug

    C134

    go.drugbank.com/drugs/DB18261
    Experimental

    C134 is a genetically engineered oncolytic herpes simplex virus expressing human cytomegalovirus (HCMV) internal repeat short 1 (IRS1).

  10. Drug

    BREN-02

    go.drugbank.com/drugs/DB18264
    Experimental

    BREN-02 is a recombinant human homeoprotein Engrailed 1 (rhEN1).